{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.15","upperLimit":"32.06","value":"17.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Complete response rate (CRR) is defined as the percentage of complete responses estimated by the total number of patients who achieve a complete response by day 100 post-transplant divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true complete response rate at day 100 will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"CONDITIONING: Patients receive 56 mg/m\\^2 carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3. TRANSPLANT: Patients undergo autologous stem cell transplant on day 0. Autologous Bone Marrow Transplantation: Undergo autologous stem cell transplant. Autologous Hematopoietic Stem Cell. Transplantation: Undergo autologous stem cell transplant, Carfilzomib: Given IV. Laboratory Biomarker Analysis: Correlative studies, Melphalan: Given IV","id":"OG000","title":"Dose Level 3"}],"paramType":"NUMBER","populationDescription":"All patients treated at dose level 3","reportingStatus":"POSTED","timeFrame":"At day 100","title":"Complete Response Rate at Day 100","type":"SECONDARY","unitOfMeasure":"percentage of patients"}